Fifty years of clinical use of warfarin;Cincuenta años de uso clínico de la warfarina

Investigacion Clinica

Volumn 51, Issue 2, 2010, Pages 269-287

  Quintero González, Jesús Alberto ^a  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

INR; Oral anticoagulant; Thrombosis; Warfarin

Indexed keywords

VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

BLEEDING; DOSE RESPONSE; DRUG INTERACTION; DRUG MONITORING; HUMAN; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; THROMBOSIS; VITAMIN INTAKE; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FOOD DRUG INTERACTION; HISTORY; INTERNATIONAL NORMALIZED RATIO; METABOLISM; PATIENT EDUCATION; THROMBOPHILIA;

ANTICOAGULANTS; DRUG INTERACTIONS; DRUG MONITORING; FOOD-DRUG INTERACTIONS; HEMORRHAGE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; PATIENT EDUCATION AS TOPIC; THROMBOPHILIA; THROMBOSIS; VITAMIN K; WARFARIN;

EID: 78149253602     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Schofield FW. A brief account of a disease in cattle simulating haemorrhagic septicaemia due to feeding sweet clover. Can Vet Rec 1922; 3:74-78.
2. Roderick LM. A problem in the coagulation of the blood: "sweet clover disease of cattle". Am J Physiol 1931; 96:413-425.
3. Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV: The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941; 138: 21-33.
4. Campbell HA, Smith WK, Roberts WL, Link KP. Studies on the hemorrhagic sweet clover disease. II: The bioassay of hemorrhagic concentrates by following the prothrombin level in the plasma of rabbit blood. J Biol Chem 1941; 138:1-20.
5. Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19(1):97-107.
6. O'Reilly RA. Studies of optical enatiomorphs of warfarin in man. Clinical Pharmacol Ther 1974; 16:348-354.
7. Breckenridge A. Oral anticoagulant drugs: Pharmacokinetic aspects. Semin Haematol 1978; 15:19-26.
8. O'Reilly RA. Interaction of the oral anticoagulant drug warfarin and its metabolites with human plasma albumin. J Clin Invest 1969, 48:193-202.
9. Breckenridge A. Oral anticoagulant - the totem and the taboo. Br Med J 1976; 1: 419-423.
10. Lewis RJ, Trager WF, Robinson AJ, Chan KK. Warfarin metabolites the anticoagulant activity and pharmacology of warfarin alcohols. J Lab Clin Med 1973; 81:925-931.
11. Koch-Weser J. Hemorrhagic reactions and drug reactions in 500 warfarin-treated patients. Clin Pharmacol Ther 1973; 14:139.
12. Starr KJ, Petrie JC. Drug interactions in patients on long-term anticoagulant and antihypertensive adrenergic neuron blocking drugs. Br Med J 1972; 4:133-135.
13. Bechtold H, Andrassy K, Jahnchen E, Koderisch J, Koderisch H, Weilemann LS, Sonntag HG, Ritz E. Evidence for impaired hepatic vitamin k1 metabolism in patients treated with N-methylthiotetrazole cephalosporins. Thromb Haemost 1984; 51:358-361.
14. O'Really. The stereoselective interaction of warfarin and metronidazole. N Engl J Med 1976; 295:354-357.
15. Christenson LK, Skovsted L. Inhibition of drugs metabolism by chloramphenicol. Lancet 1976; 2:1397-1399.
16. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients received longterm anticoagulants. Clin Pharmacol 1989; 8:210-214.
17. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980; 302:33-35.
18. Woldtvedt BR, Cahoon CL, Bradley LA, Miller SJ. Possible increased anticoagulation effect of warfarin induced by azithromycin. Ann Pharmacother 1998; 32:269-270.
19. Fausa O. Salicylate-induced hypoprothrombinemia. A report of four cases. Acta Med Scand 1979; 188:403-408.
20. Sellers EM, Koch-Weser J. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic and nalixidic acids. Clin Pharmacol Ther 1970; 11:524-529.
21. Mersfelder T, Steward L. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34:325-327.
22. Tempero KF, Cirillo VJ, Steelman SL. Diflunisal: A review of pharmacokinetic and pharmacodynamic properties, drug interactions and special tolerability studies in humans. Br J Clin Phamacol 1977; 4:315-365.
23. Ravic M Johnston A, Turner P, Ferber HP. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 1990; 9:413-414.
24. Rhodes RS, Rhodes PJ, Klein C, Sintek CD. A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm 1985; 19:556-558.
25. Schwartz J, Bugianesi K, Ebel D, De Smet M, Haesen R, Larson P, Ko A Verbesselt R, Hunt T, Lins R, Lens S, Porras A, Dieck J, Keymeulen B, Gertz B. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 2000; 68:626-636.
26. Carter SA. Potential effect of sulindac on response of prothrombin time to oral anticoagulants. Lancet 1979; 11:698.
27. Rees A, Dalal JJ, Reid PG, Henderson AH. Dangers of amiodarone and anticoagulant treatment. Br Med J 1981; 282:1756-1757.
28. Gazzaniga A, Stewart D. Possible quinidine induced haemorrhage in a patient on warfarin sodium. N Engl J Med 1969; 280:711.
29. Hansen J, Siersboek-Nielsen E, Skovstedt L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971; 12:539-543.
30. Nappi JM. Warfarin and phenytoin interaction. Ann Intern Med 1979; 90:852.
31. Black DJ, Gidal BE, Seaton TL. An evaluation of the effect of fluconazole on the stereoselective metabolism of warfarin. Clin Pharmacol Ther 1992; 51:184.
32. Cullen SI, Catalano PM. Griseofulvin-warfarin antagonism. JAMA 1967; 199: 582-583.
33. O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, Trager WF. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992; 51:656-657.
34. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol 1984; 17:559-563.
35. O'Reilly RA, Sahud MA, Aggeler PM. Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs in man. Ann NY Acad Sci 1971; 179: 173-186.
36. Serlin MJ, Sibeon RG, Mossman S, Breckenridge A, Williams J, Atwood J, Willoughby J. Cimetidine: interaction with oral anticoagulants in man. Lancet 1979; 2:317-319.
37. Sutfin T, Balmer K, Bostrom N, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11:176-184.
38. Braverman S, Marino M. Sucralfate-warfarin interaction. Drug Intell Clin Pharm 1988; 22:913.
39. Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. Br Med J 1987; 295:1.141.
40. Adachi Y, Yokoyama Y, Nanno T, Yamamoto T. Potentiation of warfarin by interferon. Br Med J 1995; 311:292.
41. Oliver MF, Roberts SD, Hayes D, Pantridge JF, Suzman MM, Bersohn I. Effect of atromid and ethyl chlorophenoxy-isobutyrate on anticoagulant requirements. Lancet 1963; 1:143.
42. Gross I, Brotman M. Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy. Ann Intern Med 1970; 72:95.
43. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996; 30:1399-1402.
44. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 1992; 340:979-980.
45. Ahmad S. Lovastatin. Warfarin interaction. Arch Intern Med 1990; 150:2407.
46. Rawlins M, Smith M. Influence of allopurinol on drug metabolismo in man. Br J Pharmacol1981; 48:693-98.
47. Acomb C, Shaw, PW. A significant interaction between warfarin and stanozolol. Pharm J 1985; 284:73.
48. Koch-Weser J. Potentiation by glucagon of the hypoprothrombinemic action of warfarin. Ann Intern Med 1970; 72:331.
49. Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med 1962; 266:76-79.
50. Bruning PF Bonfrer JGM. Aminoglutethimide and oral anticoagulant therapy. Lancet 1983; 2:582.
51. Lewis RJ. Effect of barbiturates on anticoagulant therapy. N Engl J Med 1966; 274:110.
52. Morreale A, Janetzky K. Probable interaction of warfarine and acarbose. Am J Health Syst Pharm 1997; 54:1551-1552.
53. Rothstein E. Warfarin effect enhanced by disulfiram. JAMA 1968; 206:1574.
54. Davis JW, Johns LE. Possible interaction of sulphinpyrazone with coumarins. N Engl J Med 1978; 299:955.
55. Borowski M, Furie BC, Bauminger S, Furie B. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. J Biol Chem 1986; 261:14969-14975.
56. Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98:120-125.
57. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 1982; 257:11210-11212.
58. Furie B, Furie BC. Molecular basis of vitamin- k-dependent γ carboxylation. Blood 1990; 75:1753-1762.
59. Deykin D, Wessler S, Reimer SM. Evidence of an antithrombotic effect of dicoumarol. Am J Physiol 1960; 199:1161-1164.
60. McGehee WG, Klotz TA, Epteins DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 101:59-60.
61. WHO. Expert Committee on Biological Standardization. Thirty-third Report. World Health Organ Tech Rep Sev 1983: 81-105.
62. Loeliger EA, Poller L, Samama M, Thomson JM, Van den Besselaar AM, Vermylen J, Verstraete M. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985; 54:515-517.
63. O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: Initiation of warfarin therapy without a loading dose. Circulation 1968; 38:169-177.
64. Davidson JF, Colvin BT, Barrowcliffe TW, Kernoff PBA, Machin SJ, Poller L, Preston FE, Walker ID, Mibashan RS, Shinton NK. Guidelines on oral anticoagulation. J Clin Pathol 1990; 143:177-183.
65. Deykin D. Warfarin therapy. N Engl J Med 1970; 283:691-694.
66. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg J. Anti- thrombotic therapy for venous thromboembolic disease. Chest 2001; 119:176S-193S.
67. Singer DE. Randomized trials of warfarin for atrial fibrillation. N Engl J Med 1992; 327:1451-1453.
68. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001,119:194S-206S.
69. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001; 119:220S-227S.
70. Cairns JA, Théroux P, Lewis HD, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest 2001; 119:228S-252S.
71. Smith P, Anersen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323:147-152.
72. Powers PJ, Gent M, Jay RM, Julian DH, Turpie AG, Levine M, Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Inter Med 1989; 149:771-774.
73. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, PREVENT Investigators. Long-term, Low-Intensity Warfarin Therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348(15):1425-1434.
74. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M, Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity Warfarin therapy with conventional-intensity Warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631-639.
75. Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized controlled trials. J Inter Med 2000; 247(5):553-562.
76. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP, Investigators of the "Durée Optimale du Traitement Anti- Vitamines K" (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103(20):2453-2460.
77. Kearon C, Ginsberg J, Anderson D, Kovacs M, Wells P, Julian J, Mackinnon B, Demers C, Douketis J, Turpie A, Van Nguyen P, Green D, Kassis J, Kahn S, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz J, Hirsh J, Gent M. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2:743-749.
78. British Committee for Standards in Haematology. Guidelines on oral anti-coagulation (warfarin): third edition-2005.
79. Agnelli G, Prandoni P, Santamaría M, Bagatella P, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345:165-169.
80. Baglin T, Luddintong R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362:523-526.
81. Couris RR, Tataronis GR, Booth SL, Dallal GE, Blumberg JB, Dwyer JT. Development of a selfassessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll Nutr 2000; 19(6):801-806.
82. Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81(3):396-399.
83. Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 1993; 23(2):77-82.
84. Cropp J, Bussey H. A review of enzyme induction of warfarin metabolism with recommendations for patients management. Pharmacotherapy 1997; 17(5):917-928.
85. Casner P, Sandoval E. Increased sensitivity to warfarin in elderly hispanics. J Clin Pharmacol 2002; 42:145.
86. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995; 40(3):203-207.
87. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003; 3: 202-214.
88. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis. Genet Med 2005; 7(2):97-104.
89. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22):2285-2293.
90. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2):645-649.
91. Linkins LA, Choi PT, Daeketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139:893-900.
92. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124:970-979.
93. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for out-patients treated with warfarin. J Gen Intern Med 1998; 13:311-316.
94. Mosley DH, Schatz IJ, Breneman GM, Keyes JW. Long-term anticoagulant therapy: Complications and control in a review of 987 cases. JAMA 1963; 186: 914-916.
95. Pastor BM, Resnick ME, Rodman T. Serious hemorrhagic complications of anticoagulant therapy. JAMA 1962; 180:747-751.
96. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104:390-398.
97. Hirch J. Oral anticoagulant drugs. N Engl J Med 1991; 324; 1.865-1.874.
98. Silverstein A. Neurological complications of anticoagulant therapy. A neurologist's rewiew. Arch Intern Med 1979; 139:217-220.
99. Chan Y, Valentin D, Mansfield A. Warfarin induced skin necrosis. Br J Surg 2000; 87:266-272.
100. Cole M, Minifee P, Wolman F. Coumarin necrosis-a review of the literature. Surgery 1988; 103:271-277.
101. Chan WS, Anaud S, Gingsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160:191-196.
102. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68:122-140.
103. Vitale N, De Feo M, De Santo, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33:1637-1641.
104. Salazar E, Izaguirre R. Heart disease, anticoagulants and pregnancy. Rev Esp Cardiol 2001; 54(Supl.1):8-16.
105. Sareli P, England MJ, Berk MR, Marcus RH, Epstein M, Driscoll J, Meyer T, McIntyre J, van Gelderen C. Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prostheses. Am J Cardiol 1989; 63:1462-1465.